MedTrace Logo

Safety of Lymph Node Injection for Allergen Immunotherapy

NCT01982474 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-02-09

No results posted yet for this study

Summary

The purpose of this study is to determine safety of allergy immunotherapy lymph node injections for grass pollen allergies.

Conditions

  • Allergic Rhinitis

Interventions

BIOLOGICAL

Grass pollen extract

Grass pollen extract injected intralymphatically q 4 weeks x 3

OTHER

Placebo injection

Normal saline injected intralymphatically q 4 weeks x 3

Sponsors & Collaborators

  • Nationwide Children's Hospital

    collaborator OTHER

  • Amber Patterson

    lead OTHER

Principal Investigators

  • Amber M Patterson, MD · Nationwide Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01982474 on ClinicalTrials.gov